KLOW is not a single molecule. It is a combination product that pools four separate research peptides in one vial: BPC-157 (a synthetic pentadecapeptide), TB-500 (the research label for thymosin beta-4 or an actin-binding fragment of it), GHK-Cu (the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine), and KPV (the lysine-proline-valine C-terminal fragment of α-MSH).1257 It is supplied in Canada strictly as a research-use-only material and is not an approved drug for human or veterinary use in any jurisdiction.
Vendors typically market KLOW around an 80 mg total fill, often as roughly GHK-Cu 50 mg with BPC-157, TB-500, and KPV at about 10 mg each, though ratios vary by supplier and are not standardized. The rationale given for combining them is that each component has been studied for a different facet of tissue repair, inflammation, or matrix remodeling. Critically, the blend itself has not been studied in any peer-reviewed trial; everything below is drawn from the individual-component literature and is graded conservatively as C because the combination’s safety, interactions, and efficacy are not established.
Sequence & identity
A four-peptide blend, not a single formula: BPC-157 (GEPPPGKPADDAGLV) · TB-500 / thymosin β4 (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES) · GHK-Cu (Gly-His-Lys·Cu²⁺) · KPV (Lys-Pro-Val).
Mechanisms studied
The four peptides act through unrelated mechanisms; no study describes how they interact when combined. The mechanisms below are reported for each component individually.
BPC-157. In cell and animal models, researchers reported that BPC-157 promotes angiogenesis, with work describing increased VEGFR2 expression and signaling through the Akt–eNOS (nitric oxide) axis, alongside effects on fibroblast activity and blood-vessel formation at injury sites.19 These are preclinical observations; human mechanistic data are lacking.
TB-500 (thymosin β4). Reviewers report that thymosin β4 binds and sequesters monomeric G-actin, regulating actin polymerization and cell motility, and that it promotes endothelial migration, angiogenesis, and keratinocyte chemotaxis in injury models.2 Characterized chiefly in cell and animal systems.
GHK-Cu. Researchers report that GHK binds copper(II) with high affinity and delivers it intracellularly in a redox-silenced form, and that in fibroblast and tissue models it stimulates synthesis of collagen and proteoglycans (including decorin) while modulating matrix metalloproteinases and their TIMP inhibitors.5 Largely in-vitro, animal, and topical-cosmetic data.
KPV. Dalmasso and colleagues observed that KPV is carried into cells by the PepT1 di/tripeptide transporter and then suppresses the NF-κB inflammatory pathway, with Land reporting that KPV blocks the p65/RelA–importin-α3 interaction and reduces downstream IL-8 in bronchial epithelial cells.710 Animal and in-vitro only.
Dosing in the research literature
The figures below summarise regimens as reported in published research — they are not recommendations or directions for use.
| Source / model | Regimen reported | Notes |
|---|---|---|
| BPC-157 component — animal models (e.g. rodent tendon/gut injury studies summarized in reviews) | Rodent studies typically used microgram-per-kilogram to low-milligram-per-kilogram BPC-157 given intraperitoneally, intragastrically, or locally.19 | Component study parameter, not a blend direction. Animal-model dosing; no validated human dose exists. RUO only. |
| TB-500 / thymosin β4 component — Sosne et al., Cornea 2015 (Phase 2) and Ruff et al. 2010 (Phase 1 IV) | Topical 0.1% ophthalmic Tβ4 dosed 6×/day for 28 days (dry-eye trial); separately, single IV doses of 42–1260 mg in healthy volunteers (pharmacokinetics).1112 | Component study parameters for thymosin β4 alone, not for KLOW. These topical/IV research administrations do not define a blend regimen. |
| GHK-Cu component — topical cosmetic trials (Pickart & Margolina 2015 review) | GHK-Cu formulated into face/eye/thigh creams and applied topically over about 12 weeks in cited cosmetic studies.5 | Component parameter from topical cosmetic research; per-application amounts vary by product. No established injectable or systemic GHK-Cu dose, and none for the blend. |
| KPV component — Dalmasso et al. 2008 (murine & in-vitro) | 100 µM KPV in mouse drinking water (colitis models); 10 nM KPV in epithelial/immune cell culture.7 | Component study parameter, not a blend direction. Experimental concentrations in animals/cells only; no human dose established. |
| KLOW blend (the combined product) | Not established | There is no published study of the KLOW combination, so no blend regimen, route, ratio, or safety profile is defined in the peer-reviewed literature. Vendor fills (e.g. ~80 mg total, often GHK-Cu-heavy) are commercial choices, not research-derived directions. RUO only. |
Effects observed in research
No combined effect of KLOW has been demonstrated. The observations below are per-component and come from laboratory and, where noted, limited human settings; they are not claims of benefit and have not been shown to translate to humans for the blend.
For BPC-157, a 2025 systematic review reported improved outcomes across muscle, tendon, ligament, and bone injury endpoints in preclinical (animal) studies, while noting that robust human data are absent.9 For TB-500 / thymosin β4, animal models reported accelerated dermal wound closure and angiogenesis, and a Phase 2 trial reported reduced signs and symptoms of severe dry eye with a topical formulation.211 For GHK-Cu, small topical cosmetic trials reported improvements in skin firmness, density, and wrinkle parameters.5 For KPV, murine colitis models reported reduced colonic inflammation (e.g. roughly half the myeloperoxidase activity) and lower pro-inflammatory cytokine signaling.7 None of the four has an approved human indication, and the blend is not approved to diagnose, treat, cure, or prevent any condition.
Strength of evidence
Evidence grade C, and specifically: blends like KLOW have essentially no direct study. A literature search returns no peer-reviewed trial of the four-peptide combination — not for efficacy, not for safety, and not for pharmacokinetic or chemical interactions between the components. Every statement above rests on the individual-component record. Within that record the components are uneven: thymosin β4 and GHK-Cu carry Grade B evidence (some controlled human trials, mostly topical, plus extensive preclinical work), whereas BPC-157 and KPV carry Grade C evidence (animal and in-vitro data with no completed efficacy trials in humans).2579 Combining peptides does not combine their evidence; if anything it adds uncertainty, because interactions, stability in a shared vehicle, and a combined safety profile are all unstudied. The overall blend is therefore graded conservatively as C. This material is research-use-only.
Reconstitution & storage
Reconstitute with bacteriostatic water for laboratory handling. Store lyophilised material frozen and reconstituted material refrigerated. Use Peptigo’s reconstitution calculator and storage cheat sheet for working figures.
References
- Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. doi:10.3389/fphar.2021.627533. https://pmc.ncbi.nlm.nih.gov/articles/PMC8027550/
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004. https://pubmed.ncbi.nlm.nih.gov/16099219/
- National Center for Biotechnology Information. PubChem Compound Summary for CID 9941957, BPC-157 (C62H98N16O22; InChIKey HEEWEZGQMLZMFE-RKGINYAYSA-N; CAS 137525-51-0). https://pubchem.ncbi.nlm.nih.gov/compound/9941957
- National Center for Biotechnology Information. PubChem Compound Summary for CID 45382195, Thymosin beta-4. https://pubchem.ncbi.nlm.nih.gov/compound/45382195
- Pickart L, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108. PMID:26236730. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
- National Center for Biotechnology Information. PubChem Compound Summary for CID 71587328, GHK-Cu (copper tripeptide-1). https://pubchem.ncbi.nlm.nih.gov/compound/71587328
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026. PMID:18061177. https://pubmed.ncbi.nlm.nih.gov/18061177/
- National Center for Biotechnology Information. PubChem Compound Summary for CID 125672, Lys-Pro-Val (KPV). https://pubchem.ncbi.nlm.nih.gov/compound/125672
- Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. doi:10.3390/ph18020185. PMID:40005999. https://pubmed.ncbi.nlm.nih.gov/40005999/
- Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. PMID:22837805. https://pmc.ncbi.nlm.nih.gov/articles/PMC3403564/
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496. doi:10.1097/ICO.0000000000000379. PMID:25826322. https://pubmed.ncbi.nlm.nih.gov/25826322/
- Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. doi:10.1111/j.1749-6632.2010.05474.x. PMID:20536472. https://pubmed.ncbi.nlm.nih.gov/20536472/